Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence
In the authors' words
The absence of accurate, noninvasive, scalable screening tools keeps early esophageal cancer (EC) detection a global health challenge. Although noncontrast computed tomography (NC CT) is widely accessible, the esophagus is a hollow tubular structure prone to collapse and motion artifacts, making small early malignant lesions difficult to distinguish from normal tissue. Here we developed the Esophageal AI-Guided malignant Lesion Evaluation (EAGLE) model to detect precancerous lesions and cancer from chest NC CT, a task historically considered impossible. EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and population-based screening settings. For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensitivity for cancer and 52.5% for precancerous lesions; low-dose CT (LDCT) validation (two centers, n = 1,607) showed comparable performance, supporting EC screening through lung-cancer screening programs. Calibration in a real-world cohort (three centers, n = 35,402) reduced false positives by 72.7% while preserving sensitivity; prospective hospital validation (n = 17,446) achieved a 42.2% PPV, and real-world low-dose screening (n = 10,959) reached 99.94% specificity. EAGLE also detected precancerous lesions-in paired CT-endoscopy cohorts (two centers, n = 702), sensitivities were 65.0% for precancerous lesions and 78.4% for stage I EC at a higher-sensitivity operating point. Exploratory analyses of a prospectively enrolled cohort suggest that referring high-risk individuals for endoscopy could improve screening efficiency. In conclusion, EAGLE has the potential to serve as a scalable tool for early EC screening. Chictr.org.cn identifier: ChiCTR2300074806 .
In plain words AI summary
For cancer detection on existing CT scans, the model achieved 90.0% sensitivity and 98.5% specificity. In real-world low-dose screening, it reached 99.94% specificity, and calibration reduced false positives by 72.7%. The authors conclude that EAGLE has the potential to serve as a scalable tool for early esophageal cancer screening.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source. 2 sentences were removed for not being supported by the abstract.
Appeared: Thursday, September 24. Nature Medicine. Peer-reviewed journal.